Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH2)

International Journal of Biochemistry and Cell Biology

Volumn 36, Issue 9, 2004, Pages 1848-1859

  Balzarini, Jan ^a   Andersson, Elin ^b   Schols, Dominique ^a   Proost, Paul ^a   Van Damme, Jo ^a   Svennerholm, Bo ^b   Horal, Peter ^b   Vahlne, Anders ^c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Ala; alanine; CD26; Dipeptidyl peptidase IV; G NH2; G NH2 prodrug; glycinamide; glycylprolylglycinamide; GPG NH2; HIV; human immunodeficiency virus; Pro; proline; SDS PAGE

Indexed keywords

AMIDE; ANTIRETROVIRUS AGENT; CELL SURFACE PROTEIN; DIPEPTIDYL PEPTIDASE IV; DIPROTIN A; ENZYME INHIBITOR; GLUTAMINE; GLUTAMINYLPROLYLGLYCINAMIDE DERIVATIVE; GLYCINAMIDE; GLYCYLPROLINE; GLYCYLPROLYLGLYCINAMIDE; ISOLEUCYLPYRROLIDINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CATTLE; CELL CULTURE; CELL SUSPENSION; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE; PROTEIN EXPRESSION; TARGET CELL; VIRUS REPLICATION;

ADENOSINE DEAMINASE; ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD26; CATTLE; CELLS, CULTURED; ENZYME INHIBITORS; FETAL BLOOD; GLYCOPROTEINS; HIV-1; HIV-2; HUMANS; ISOLEUCINE; OLIGOPEPTIDES; PROLINE; SERUM; T-LYMPHOCYTES;

BOVINAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE;

EID: 2942622362     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.02.017     Document Type: Article

References (22)

1. Blanco J., Nguyen C., Callebaut C., Jacotot E., Krust B., Mazaleyrat J.P., et al. Dipeptidyl-peptidase IV-β - Further characterization and comparison to dipeptidyl-peptidase IV activity of CD26. European Journal of Biochemistry. 256:1998;369-378
2. Christopherson K.W. II, Hangoc G., Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. Journal of Immunology. 169:2002;7000-7008
3. De Meester I., Vanhoof G., Lambeir A.-M., Scharpé S. Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5). Journal of Immunology Methods. 189:1996;99-105
4. De Meester I., Korom S., Van Damme J., Scharpe S. CD26, let it cut or cut it down. Immunology Today. 20:1999;367-375
5. Duke-Cohan J.S., Morimoto C., Rocker J.A., Schlossman S.F. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. Journal of Immunology. 156:1996;1714-1721
6. Durinx C., Lambeir A.-M., Bosmans E., Falmagne J.-B., Berghmans R., Haemers A., et al. Molecular characterization of dipeptidyl peptidase activity in serum. Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. European Journal of Biochemistry. 267:2000;5608-5613
7. Fox D.A., Hussey R.E., Fitzgerald K.A., Acuto O., Poole C., Palley L., et al. Ta1, a novel 105 kDa human T cell activation antigen defined by a monoclonal antibody. Journal of Immunology. 132:1984;1250-1256
8. Höglund S., Su J., Reneby S.S., Vegvari A., Hjertén S., Sintorn I.-M., et al. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrobial Agents and Chemotherapy. 46:2002;3597-3605
9. Horal P., Hall W.W., Svennerholm B., Lycke J., Jeansson S., Rymo L., et al. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proceedings of the National Academic Sciences of United States of America. 88:1991;5754-5758
10. Mentlein R. Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides. Regulatory Peptides. 85:1999;9-24
11. Ohtsuki T., Hosono O., Kobayashi H., Munakata Y., Souta A., Shioda T., et al. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidyl peptidase IV. FEBS Letters. 431:1998;236-240
12. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. Journal of Experimental Medicine. 186:1997;1865-1872
13. Proost P., De Meester I., Schols D., Struyf S., Lambeir A.-M., Wuyts A., et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. Journal of Biological Chemistry. 273:1998;7222-7227
14. Proost P., Struyf S., Schols D., Durinx C., Wuyts A., Lenaerts J.-P., et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Letters. 432:1998;73-76
15. Schols D., Proost P., Struyf S., Wuyts A., De Meester I., Scharpé S., et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Research. 39:1998;175-187
16. Senten K., Van der Veken P., Bal G., De Meester I., Lambeir A.-M., Scharpé S., et al. Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorganic & Medical Chemistry Letters. 12:2002;2825-2828
17. Su J., Palm A., Wu Y., Sandin S., Höglund S., Vahlne A. Deletion of the GPG motif in the HIV type 1 V3 loop does not abrogate infection in all cells. AIDS Research and Human Retroviruses. 16:2000;37-48
18. Su J., Andersson E., Horal P., Naghavi M.H., Palm A., Wu Y.-P., et al. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1. Journal of Human Virology. 4:2001;1-7
19. Su J., Naghavi M.H., Jejcic A., Horal P., Furuta Y., Wu Y.-P., et al. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication. Journal of Human Virology. 4:2001;8-15
20. Vanham G., Kestens L., De Meester I., Vingerhoets J., Penne G., Vanhoof G., et al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. Journal of Acquired Immune Deficiency Syndrome. 6:1993;749-757
21. Vanhoof G., Goossens F., De Meester I., Hendriks D., Scharpe S. Proline motifs in peptides and their biological processing. FASEB Journal. 9:1995;736-744
22. Yaron A., Naider F. Proline-dependent structural and biological properties of peptides and proteins. Critical Review of Biochemical and Molecular Biology. 28:1993;31-81